A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling
Phase 1/2 Completed
29 enrolled
Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Phase 1/2 Completed
45 enrolled
Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts
Phase 1/2 Completed
16 enrolled 14 charts
Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma
Phase 1/2 Completed
24 enrolled 18 charts
A Study Evaluating Safety, Tolerability, and Clinical Activity of Forimtamig-Based Treatment Combinations in Participants With Relapsed or Refractory Multiple Myeloma
Phase 1/2 Completed
19 enrolled
PG2 Phase I/II Clinical Study Intravenously Administered in Patients With Advanced Malignancy
Phase 1/2 Completed
32 enrolled
LUPER
Phase 1/2 Completed
28 enrolled
RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
Phase 1/2 Completed
29 enrolled
Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL (JACKPOT8)
Phase 1/2 Completed
171 enrolled 23 charts
Safety/Efficacy Study of Imprime PGG With Cetuximab in Patients With Recurrent/Progressive Colorectal Carcinoma
Phase 1/2 Completed
32 enrolled 23 charts
p53 Suppressor Activation in Recurrent High Grade Serous Ovarian Cancer, a Phase Ib/II Study of Systemic Carboplatin Combination Chemotherapy With or Without APR-246
Phase 1/2 Completed
247 enrolled 15 charts
KEYNOTE-B84
Phase 1/2 Completed
49 enrolled
MB-CART20.1 Lymphoma
Phase 1/2 Completed
10 enrolled
Study of Brentuximab Vedotin (SGN-35) in Pediatric Participants With Relapsed or Refractory (r/r) Systemic Anaplastic Large-Cell Lymphoma or Hodgkin Lymphoma
Phase 1/2 Completed
36 enrolled 26 charts
Combination Therapy With Carfilzomib, Romidepsin, Lenalidomide in Patients With Relapsed or Refractory B- and T-cell Lymphomas
Phase 1/2 Completed
27 enrolled 13 charts
Umbilical & Cord Blood (CB) Derived CAR-Engineered NK Cells for B Lymphoid Malignancies
Phase 1/2 Completed
49 enrolled 12 charts
Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients
Phase 1/2 Completed
45 enrolled
Study of Lenvatinib in Combination With Everolimus in Recurrent and Refractory Pediatric Solid Tumors, Including Central Nervous System Tumors
Phase 1/2 Completed
64 enrolled 29 charts
A Study of Oral Rucaparib in Patients With a Solid Tumor (Phase I) or With gBRCA Mutation Ovarian Cancer (Phase II)
Phase 1/2 Completed
136 enrolled 30 charts
A Study to Investigate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Immunogenicity of TAK-079 Administered Subcutaneously as a Single Agent in Participants With Relapsed/Refractory (r/r) Multiple Myeloma (MM)
Phase 1/2 Completed
50 enrolled 26 charts
Pyrimethamine for the Treatment of Relapsed Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Phase 1/2 Completed
20 enrolled 9 charts
Biological Therapy in Treating Patients at High-Risk or With Lymphoma, Lymphoproliferative Disease, or Malignancies
Phase 1/2 Completed
58 enrolled 18 charts
Dose-escalation Study of Safety of PBCAR20A in Subjects With r/r NHL or r/r CLL/SLL
Phase 1/2 Completed
18 enrolled 13 charts
Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma
Phase 1/2 Completed
28 enrolled 10 charts
Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
Phase 1/2 Completed
39 enrolled
Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT)
Phase 1/2 Completed
12 enrolled
NB1011 Administered by Continuous Infusion in Cancers That Overexpress Thymidylate Synthase (TS)
Phase 1/2 Completed
155 enrolled
Mocetinostat (MGCD0103) Plus Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Hodgkin Lymphoma
Phase 1/2 Completed
7 enrolled 10 charts
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
Phase 1/2 Completed
53 enrolled 17 charts
BV-ICE
Phase 1/2 Completed
53 enrolled
Gemcitabine and Bendamustine in Patients With Relapsed or Refractory Hodgkin's Lymphoma
Phase 1/2 Completed
26 enrolled 13 charts
Lenalidomide, Dexamethasone and Cyclophosphamide in Amyloidosis (AL)
Phase 1/2 Completed
37 enrolled
Sorafenib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Leukemia
Phase 1/2 Completed
70 enrolled 26 charts
Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in Osteosarcoma
Phase 1/2 Completed
18 enrolled 11 charts
A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.
Phase 1/2 Completed
29 enrolled
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
Phase 1/2 Completed
17 enrolled 14 charts
Phase 1/2 Safety and Efficacy of PLX3397 in Adults With Relapsed or Refractory Acute Myeloid Leukemia (AML)
Phase 1/2 Completed
90 enrolled 23 charts
LeMLAR
Phase 1/2 Completed
37 enrolled
Clofarabine, Idarubicin, and Cytarabine (CIA) Versus Fludarabine, Idarubicin, and Cytarabine (FLAI) in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome
Phase 1/2 Completed
282 enrolled 13 charts
Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer
Phase 1/2 Completed
21 enrolled
Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant
Phase 1/2 Completed
37 enrolled
Phase Ib Study of Chiauranib in Patients With Ovarian Cancer
Phase 1/2 Completed
25 enrolled
Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders
Phase 1/2 Completed
31 enrolled
Phase 1 and 2 Study of PX-866 and Cetuximab
Phase 1/2 Completed
178 enrolled
Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments
Phase 1/2 Completed
39 enrolled
Deno-ABC
Phase 1/2 Completed
6 enrolled
Carboplatin/Pralatrexate in Recurrent Platinum-Sensitive Ovarian, Fallopian or Primary Peritoneal Cancer
Phase 1/2 Completed
50 enrolled 15 charts
Safety and Tolerability Study of Voreloxin and Cytarabine Combination in Acute Myeloid Leukemia in Humans
Phase 1/2 Completed
110 enrolled 15 charts
Cabozantinib (XL184) in Patients With Relapsed or Refractory Myeloma
Phase 1/2 Completed
11 enrolled 12 charts
Inhalation SLIT Cisplatin (Liposomal) for the Treatment of Osteosarcoma Metastatic to the Lung
Phase 1/2 Completed
19 enrolled 8 charts